Labcorp Launches New Amyloid-Tau-Neurodegeneration Biomarker Blood Test

Labcorp has announced that its ATN Profile (Laboratory Corporation of America Holdings, Burlington, NC) test for identifying and assessing biological changes in blood biomarkers associated with Alzheimer disease (AD) has launched and is available in the United States. Physicians can use the tests to evaluate patients for pathologies associated with AD and other neurodegenerative conditions.

ATN Profile specifically includes tests for amyloid plaques (Aß42/40), tau tangles (pTau 181), and neurodegeneration (neurofilament light chain [NfL]), 3 biomarkers collectively referred to as ATN. According to Labcorp, this method decreases the amount of time for identifying AD-associated biological changes as compared to the standard approach, which requires physical examination, routine blood and urine tests, and cognitive testing. ATN Profile is intended to enable physicians to interpret biomarker changes more quickly and definitively, reducing barriers to specialist referral.

“Labcorp's ATN Profile provides easier identification of biological changes consistent with Alzheimer's disease and offers the promise of an accelerated path to diagnosis," said Dr. Brian Caveney, Chief Medical and Scientific Officer of Labcorp. “This new blood biomarker test, which is widely available through physicians, will support the diagnostic and referral process for Alzheimer's disease and other neurodegenerative causes of dementia and impaired cognitive function.”

Health care providers can now order the ATN Profile, or the individual tests for its Aß42/40, pTau 181, and NfL components, from Labcorp.